COMMUNIQUÉS West-GlobeNewswire

PathAI Expands AISight Dx with v2.17 Release: Presentation Queues for Tumor Boards, Consult Workflows and Voice-Enabled Reporting
15/10/2025
BOSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- PathAI, the global leader in AI-powered pathology, today announced AISight® Dx 1 v2.17, introducing three new capabilities to its cloud-based digital pathology image management [...]
Olympia Pharmaceuticals and Wesley Pharmaceuticals Co-Founder Naomi Loomis Establishes $10,000 Scholarship for The Ohio State University’s College of Pharmacy
15/10/2025
The John Paul Dillow Scholarship will support first-generation college students at The Ohio State University’s College of Pharmacy ORLANDO, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Naomi Loomis, an alumnus of The Ohio [...]
DETERA Therapeutics Wins the Ipsen Golden Ticket 2025
15/10/2025
PRESS RELEASE DETERA Therapeutics Wins the Ipsen Golden Ticket 2025 A strategic recognition of the biotech’s potential by a leading pharmaceutical group Paris, October 15 th 2025 — DETERA Therapeutics , a biotechnology [...]
Mainz Biomed to Attend 2025 Maxim Growth Summit
15/10/2025
BERKELEY, Calif. and MAINZ, Germany, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
Artelo Biosciences Announces Expanded Clinical Data to be Presented on both ART26.12 and ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit
15/10/2025
ART26.12 Phase 1 Data Demonstrated No Safety Concerns, Predictable Linear Plasma Exposure, and Options for Dosing in Either Fed or Fasted Conditions ART27.13 Interim Phase 2 Data Showed Substantial Weight Gain and [...]
Anteris Receives First European Regulatory Clearance to Commence DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
15/10/2025
MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, [...]
Quercis Pharma and Thomas Lines Nominated for Prestigious Prix Galien USA “Best Startup” Award
15/10/2025
Recognition highlights company’s antithrombotic platform and late-stage programs designed to transform care in oncology and inflammation driven diseases ZUG, Switzerland, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Quercis Pharma [...]
Biomerica Reports First Quarter Fiscal 2026 Financial Results
15/10/2025
Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on [...]
BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit
15/10/2025
MELVILLE, N.Y., Oct. 15, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and [...]
Noom Introduces “Mindful Art Break” — A Weekly Practice Designed to Spark Awe, Relieve Stress, and Boost Psychological Wellbeing
15/10/2025
Noom open sources wellbeing by releasing its art-impact research, AI art-scoring tools, and the A.R.T. (Art Research Tool) into the public domain PRINCETON, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Noom , the leading [...]
Baylor Genetics Presents New Data on Clinical and Diagnostic Utility of RNA Sequencing for Rare Disease at the American Society of Human Genetics 2025 Annual Meeting
15/10/2025
Research underscores clinical utility of RNA sequencing in providing critical insights to drive diagnoses and medical management HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics , a clinical diagnostic [...]
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
15/10/2025
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid [...]
Le plus grand rassemblement de médecins de famille au pays posera ses valises à Winnipeg en novembre
15/10/2025
Centré sur l’amélioration des soins aux patients grâce à l’éducation, à la collaboration et à l’innovation Information sur l’événement : Forum en médecine familiale Du 5 au 8 novembre 2025 (Winnipeg) fmf.cfpc.ca/fr/ [...]
Canada’s Largest Family Medicine Gathering Comes to Winnipeg This November
15/10/2025
Focused on advancing patient care through education, collaboration, and innovation Event Information: Family Medicine Forum November 5–8, 2025 (Winnipeg) fmf.cfpc.ca MISSISSAUGA, Ontario, Oct. 15, 2025 (GLOBE NEWSWIRE [...]
Communiqué de presse : Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes
15/10/2025
Sanofi fait de Montpellier le coeur mondial de la recherche translationnelle sur les maladies auto-immunes Montpellier, 15 octobre 2025. Sanofi a lancé aujourd'hui à Montpellier un Centre d'Excellence Translationnel, en [...]
Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting
15/10/2025
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading [...]
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
15/10/2025
Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., Oct. 15, 2025 ( [...]
Amphista Therapeutics nominates AMX-883, an orally available Targeted Glue™ degrader of BRD9, as its first clinical development candidate for the treatment of acute myeloid leukaemia
15/10/2025
AMX-883 uses Amphista’s Targeted Glue™ technology, inducing degradation of BRD9 through the recruitment of DCAF16, a completely distinct mechanism of action from cereblon- or VHL-based PROTACs. The nomination of AMX-883 [...]
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
15/10/2025
ALACHUA, Fla. and TAMPA, Fla., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]

Pages